Wound closure
Diabetic, ulcer
ULCER
Wound closure started to satisfactorily appear after one month of treatment with either auto-BM-MNC or allo-WJ-MSCs, compared to the placebo group. The percentage of wound closure in participants treated with auto-BM-MNC or allo-WJ-MSC was higher than those treated with the placebo solution (Fig. Diabetic patients with CTLI treated with auto-BM-MNC, or allo-WJ-MSCs, exhibited satisfactorily wound closure of the affected limb. The percentage of wound closure in participants treated with auto-BM-MNC or allo-WJ-MSCs was higher than in those treated with the placebo solution starting from the first month of the cell-based therapy, compared to the placebo group. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (Furthermore, the data showed that patients with CLTI treated with auto-BM-MNC or allo-WJ-MSC reached more than 50% of wound closure after one month; in contrast, participants of the placebo group never achieved wound closure (Fig. At the end of the follow-up, the ulcer healing ratio was 7 of 7, 100%, for the auto-BM-MNC and allo-WJ-MSC groups. This value was significantly higher than the ratio of the placebo group (0 of 10, 0%).